Lurbinectedin is a novel anticancer agent that has been approved by the US FDA for the treatment of metastatic small cell lung cancer (SCLC) in patients who have received previous treatment. While the drug can be used as a single agent, recent studies have shown that it can be used in combination with other therapies to enhance its efficacy.

According to DrugPatentWatch [1], lurbinectedin is currently being tested in combination with several other anticancer agents, including pembrolizumab, nivolumab, and ipilimumab, in clinical trials for the treatment of various types of cancer. These trials aim to evaluate the safety and efficacy of lurbinectedin in combination with these agents and to determine the optimal dosing and treatment schedule.

A study published in the Journal of Thoracic Oncology [2] investigated the combination of lurbinectedin with doxorubicin in patients with relapsed SCLC. The study found that the combination therapy had a high response rate and was well-tolerated by patients, with manageable toxicity.

Another study published in the journal Cancer Medicine [3] evaluated the combination of lurbinectedin with gemcitabine in patients with advanced solid tumors. The study found that the combination therapy had a good safety profile and showed promising antitumor activity in patients with advanced solid tumors.

In conclusion, while lurbinectedin can be used as a single agent for the treatment of metastatic SCLC, recent studies have shown that it can also be used in combination with other therapies to enhance its efficacy. Ongoing clinical trials are evaluating the safety and efficacy of lurbinectedin in combination with other anticancer agents, and early results have shown promising antitumor activity and manageable toxicity.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795692/
[3] https://pubmed.ncbi.nlm.nih.gov/33348988/